Results for tag: "Bullous Pemphigoid Drug"

Bullous Pemphigoid (BP) is a rare, chronic, autoimmune skin disorder characterized by large, fluid-filled blisters. It is most common in elderly individuals, but can affect people of any age. Treatment for BP typically involves topical corticosteroids, systemic corticosteroids, and immunosuppressants. The BP drug market is a subset of the larger dermatological drug market. It is a small but growing market, with a focus on developing treatments that are more effective and have fewer side effects than existing treatments. Companies in this market are researching and developing new drugs, as well as reformulating existing drugs to make them more effective. Some companies in the BP drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more